Talis Biomedical Corporation
TLIS · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.01 | -0.02 |
| FCF Yield | -396.78% | -856.60% | -191.85% | -78.74% |
| EV / EBITDA | 0.66 | 0.84 | 0.67 | 0.19 |
| Quality | ||||
| ROIC | -72.27% | -70.30% | -79.61% | -49.59% |
| Gross Margin | 90.05% | -129.76% | 0.00% | 87.44% |
| Cash Conversion Ratio | 0.86 | 0.89 | 0.89 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -30.63% | -100.00% | 66.03% |
| Free Cash Flow Growth | 47.20% | 41.61% | -82.99% | -282.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.86 | 0.95 | 1.15 | 1.54 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -11,876.07 | -133.12 | -713.29 | -1,287.55 |